K
Kazuhiro Haraguchi
Researcher at Nihon Pharmaceutical University
Publications - 83
Citations - 958
Kazuhiro Haraguchi is an academic researcher from Nihon Pharmaceutical University. The author has contributed to research in topics: Uracil & Nucleophilic substitution. The author has an hindex of 17, co-authored 80 publications receiving 900 citations. Previous affiliations of Kazuhiro Haraguchi include Showa University & Kagoshima University.
Papers
More filters
Journal ArticleDOI
Genetic effects of oxidative DNA damages: comparative mutagenesis of the imidazole ring-opened formamidopyrimidines (Fapy lesions) and 8-oxo-purines in simian kidney cells
M. Abul Kalam,Kazuhiro Haraguchi,Sushil Chandani,Edward L. Loechler,Maasaki Moriya,Marc M. Greenberg,Ashis K. Basu +6 more
TL;DR: This is the first investigation using extrachromosomal probes containing a Fapy·dG or Fap·dA site-specifically incorporated, which showed unequivocally that in simian kidney cells Fapy–G→T substitutions occur at a higher frequency than 8-oxo-G →T and that Fapy ·dA is very weakly mutagenic, as is 8-Oxo-dA.
Journal ArticleDOI
Selenoxide elimination for the synthesis of unsaturated-sugar uracil nucleosides
Kazuhiro Haraguchi,Hiromichi Tanaka,Hideaki Maeda,Yoshiharu Itoh,Saito Shigeru,Tadashi Miyasaka +5 more
Journal ArticleDOI
Divergent and stereocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position
Journal ArticleDOI
Efficient removal of formamidopyrimidines by 8-oxoguanine glycosylases.
TL;DR: Differences in the activity of the various glycosylases for removal of FapyG and FapyA compared to OG in nonmutagenic versus promutagenic base pair contexts may serve to alter the mutagenic profiles of these lesions in vivo.
Journal ArticleDOI
Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine In Vitro
Takao Nitanda,Xin Wang,Hiroki Kumamoto,Kazuhiro Haraguchi,Hiromichi Tanaka,Yung-Chi Cheng,Masanori Baba +6 more
TL;DR: Since 4′-Ed4T has increased anti-HIV-1 activity, decreased cytotoxicity, and a different resistance profile, it should be considered for further development as a new member of NRTIs.